Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Carefree Pharmaceutical (also known as Jiangsu Carephar or Kefei Ping) is a Nanjing-based pharmaceutical company specializing in the development and commercialization of innovative small molecules and modern Traditional Chinese Medicine (TCM). The company is a leader in the Chinese cardiovascular market, particularly known for its flagship product, Sodium Tanshinone IIA Sulfonate. Its innovative pipeline includes Keverprazan (KFP-H008), a potassium-competitive acid blocker (P-CAB) marketed in China for duodenal ulcers and reflux esophagitis, as well as candidates targeting RORγt for autoimmune diseases and URAT1 for hyperuricemia. The company operates a comprehensive R&D platform covering drug discovery, clinical development, and GMP-certified manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu Carefree Pharmaceutical.